Therapies and Diseases
Plasma protein therapeutics help people of all ages fight chronic diseases and immune deficiency disorders. Those plasma proteins effective in treating various disorders are separated from the plasma using a series of well-established purification methods, including precipitation, centrifugation, separation and filtration. All plasma protein therapies are subject to viral removal and/or inactivation steps in the production process. These steps are effective in eliminating HIV, hepatitis and other blood-borne infectious agents. This highly complex production process requires substantial investment in equipment, training and quality control. It takes approximately seven to 12 months from the initial plasma donation to the completion of the finished therapy.
Recombinant analog therapies for bleeding disorders (antihemophilic factors) are specialized therapies for coagulation deficiencies, including Factor VII, Factor VIII and Factor IX. Recombinant therapies are genetically adapted cell cultures, where an original cell is scientifically modified (reprogrammed) to produce specific proteins. These proteins then are harvested for use in therapies.
Once the plasma is manufactured into life-saving therapies produced by the members of PPTA, these therapies help treat patients who have one of the following conditions:
- Bleeding disorders
- Immune system deficiencies
- Genetic lung disorders
- Burns
- Shock
- Trauma
- Major surgery
- Rh incompatibility
- Cardiopulmonary needs
- Recipients of transplants
- Pediatric HIV
- Hepatitis
- Serious liver conditions
- Animal bites (in the prevention of rabies)
From donors to patients, from vein to vein, plasma donors and plasma protein therapeutics help ensure a higher quality of life for people around the world who suffer from rare, often generic diseases.
Learn more about the diseases treated with plasma protein therapies.